160 Healthy International (2656) H1 2026 earnings summary

Executive summary

• H1 2026 revenue rose 9.7% YoY to RMB318.8m; operating profit was RMB5.5m and net profit RMB1.7m, versus losses in H1 2025.

• Adjusted net profit, excluding share-based compensation and listing expenses, was RMB5.5m versus an adjusted net loss of RMB5.1m.

• Digital healthcare solutions drove growth and margin improvement; the 160AI Hospital collaboration model reached commercialization and began contributing revenue.

Financial highlights

• Revenue increased from RMB290.7m to RMB318.8m; gross profit increased from RMB64.0m to RMB85.4m.

• Operating profit was RMB5.5m versus an operating loss of RMB18.0m; net profit was RMB1.7m versus a net loss of RMB19.6m.

• Adjusted net profit was RMB5.452m versus adjusted net loss of RMB5.061m; adjusted margin was 1.7% versus -1.7%.

• Cost of sales rose 3.0% to RMB233.4m; selling and marketing expenses rose 3.9% to RMB36.8m, while R&D expenses fell 11.5% to RMB15.4m.

Outlook and guidance

• Plans include international expansion, initially targeting Southeast Asia, and continued integration of AI into healthcare scenarios; no quantified financial guidance was stated.

• Plans include expanding 160AI Hospital across hospitals, upgrading its products, and developing AI-enabled patient health management and commercial models for healthcare institutions.

• A proposed growth avenue is integrated healthcare AI agent, hardware and debugging services, with potential extension into medical large language models and Token sales.

• R&D priorities include multi-agent tools and digital medical staff for patient management, clinical decision support, medical insurance calculation and hospital operations.